39 studies found for:    melanoma | Open Studies | interleukin-2
Show Display Options
Rank Status Study
21 Recruiting Study of Cell Transfer Therapy for Metastatic Melanoma Using 4-1BB Tumor Infiltrating Lymphocytes Plus IL-2 Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy
Conditions: Melanoma;   Skin Cancer
Interventions: Drug: Interleukin-2;   Drug: Fludarabine;   Drug: Cylcophosphamide;   Genetic: 41BB Selected Tumor Infiltrating Lymphocytes
22 Recruiting Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2
Condition: Metastatic Melanoma or Renal Cell Carcinoma
Intervention: Other: Boost of radiotherapy + high dose IL-2 treatment
23 Recruiting Study of Gene Modified Immune Cells in Patients With Advanced Melanoma
Condition: Metastatic Melanoma
Interventions: Biological: F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells;   Drug: non-myeloablative conditioning chemotherapy
24 Unknown  The Role of Peptide-Loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2
Condition: Metastatic Melanoma
Intervention: Procedure: Immunotherapy treatment for melanoma
25 Recruiting Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: ziv-aflibercept;   Biological: aldesleukin;   Other: laboratory biomarker analysis
26 Not yet recruiting High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: aldesleukin;   Biological: ipilimumab;   Other: laboratory biomarker analysis
27 Recruiting Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Biological: therapeutic tumor infiltrating lymphocytes;   Biological: aldesleukin;   Other: laboratory biomarker analysis
28 Recruiting Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
Condition: Metastatic Melanoma
Interventions: Drug: Ipilimumab;   Procedure: Tumor Infiltrating Lymphocytes (TIL);   Drug: Administration of Lymphodepletion;   Drug: Cyclophosphamide as Part of Lymphodepletion;   Drug: Fludarabine as Part of Lymphodepletion;   Drug: High Dose IL-2;   Biological: Adoptive Cell Therapy with TIL
29 Not yet recruiting Interleukin-2—Induced Cognitive/Affective Symptoms
Conditions: Metastatic Renal Cell Carcinoma;   Metastatic Melanoma;   High-dose Interleukin-2
Intervention:
30 Recruiting HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Condition: Metastatic Melanoma
Intervention: Drug: vemurafenib + HD IL-2
31 Unknown  Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-Depleting Chemotherapy
Condition: Metastatic Melanoma
Intervention: Biological: tumor infiltrating lymphocytes
32 Not yet recruiting Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma
Conditions: Desmoplastic Small Round Cell Tumor;   Disseminated Neuroblastoma;   Metastatic Childhood Soft Tissue Sarcoma;   Metastatic Ewing Sarcoma/PNET;   Metastatic Osteosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/PNET;   Recurrent Melanoma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma
Interventions: Biological: aldesleukin;   Biological: OKT3/humanized 3F8 bispecific antibody-activated T lymphocytes;   Biological: sargramostim;   Other: laboratory biomarker analysis
33 Recruiting Irradiated Donor Lymphocyte Infusion Plus High-dose IL-2
Condition: Metastatic Malignant Melanoma and Renal Cell Carcinoma
Intervention: Biological: Irradiated donor lymphocyte infusion
34 Recruiting Vaccine Therapy With or Without Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Interventions: Biological: NA17.A2 peptide vaccine;   Biological: recombinant MAGE-3.1 antigen;   Biological: recombinant interleukin-12;   Biological: MART-1 antigen;   Other: laboratory biomarker analysis
35 Recruiting A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma
Condition: Metastatic Melanoma Stage IV
Interventions: Drug: Arm 1: L19IL2 + Dacarbazine;   Drug: Arm 2: Dacarbazine
36 Recruiting Intratumoral Administration of L19IL2/L19TNF
Condition: Malignant Melanoma, Skin
Intervention: Drug: L19IL2+L19TNF
37 Recruiting Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients
Conditions: Solid Tumour,;   Breast Cancer,;   Metastatic Melanoma,;   Non-small Cell Lung Cancer (NSCLC),
Intervention: Drug: F16IL2 in combination with paclitaxel
38 Recruiting A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors
Conditions: Melanoma;   Prostate Cancer;   Ovarian Cancer;   Renal Cell Carcinoma;   Colorectal Carcinoma;   Pancreatic Carcinoma;   Non-small Cell Lung Carcinoma;   Solid Tumors
Interventions: Drug: AM0010;   Drug: Paclitaxel or Docetaxel and Carboplatin or Cisplatin;   Drug: FOLFOX4
39 Recruiting Trial of pIL-12 Electroporation Malignant Melanoma
Condition: Melanoma
Interventions: Biological: Plasmid INTERLEUKIN-12;   Device: Intratumoral Electroporation

Show previous page of results Previous Page (1-20) Studies Shown (21-39) Next Page
Indicates status has not been verified in more than two years